University of Massachusetts Medical School: Research to Revenue

University of Massachusetts Medical School

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 2 commercialization opportunities from University of Massachusetts Medical School and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of University of Massachusetts Medical School's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

39/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

7/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

54/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1962

First Nobel

1949

First Patent

1970

First IPO

N/A

2022-2024

mRNA vaccine licensing

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1990

First Patent

Insulin analog patent granted

1990

Drug License

Exclusive license for drug

2003

Biotech Spinoff

Founded successful biotech startup

2010

Research Collaboration

Partnership with pharma company

2015

Patent Portfolio

Expanded patent holdings

2018

Competitive Benchmarking

University of Massachusetts Medical School vs. Peer Research Universities

University of Massachusetts Medical School vs Peers Comparison

Metric	University of Massachusetts Medical School (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$327M	$855M	$1,675M
New Inventions Disclosed	1	200	400
Startups Formed	2	7	10
Visibility Index	13	12	23
Licensing Revenue	$5M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Revolutionary Cancer Immunotherapy from UMass Medical School

This breakthrough immunotherapy enhances immune response against tumors, addressing cancer treatment resistance, potentially transforming oncology care with scalable, personalized therapies.

2. Advanced Neurodegenerative Disease Biomarkers

UMass Medical School developed precise biomarkers enabling early, accurate Alzheimer's detection, improving patient outcomes and enabling scalable diagnostic solutions in a growing neurodegenerative market.

3. Novel Antiviral Therapeutics Platform

Innovative antiviral compounds target emerging viruses, addressing global infectious disease threats with scalable drug development and a strong competitive edge in pandemic preparedness.

4. AI-Driven Precision Medicine Analytics

UMass Medical School’s AI platform tailors treatments to genetic profiles, enhancing efficacy and scalability in personalized healthcare, reducing costs and improving patient outcomes.

5. Regenerative Medicine Using Stem Cell Technology

Cutting-edge stem cell therapies promote tissue regeneration, addressing chronic disease challenges with scalable, high-impact treatments and significant market potential in regenerative medicine.

6. Next-Generation Vaccine Delivery Systems

UMass Medical School’s novel delivery technology improves vaccine stability and efficacy, enabling scalable immunization programs and competitive advantage in global vaccine markets.